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Summary
Objective: The primary aim of this study was to determine the recent distribution of various
genotypes of hepatitis C virus (HCV) in patients with chronic HCV infection in Western Turkey.
Additionalobjectivesweretodeterminewhetherthereareanyassociationsofgenotypewithgender
and age, and to determine the nucleotide similarities and risk factors of non-1 HCV genotypes.
Methods: Serum samples from 345 patients (176 male, 169 female; mean age 53.3  12.7 years,
range 10—81 years) with chronic HCV infection were analyzed in this study. Viral genotypes were
determined by a restriction fragment length polymorphism (RFLP)-based in-house assay. To confirm
genotypes for the samples with band patterns other than genotype 1, the 50 UTR was amplified and
sequenced.
Results: Genotype 1 was observed in 335 of the 345 patients (97.1%). Of these, 34 patients showed
infection with subtype 1a (9.9%) and 301 with subtype 1b (87.2%). Genotypes 2, 3, and 4 were
determined in 0.9%, 1.4%, and 0.6% of the patients, respectively. Patients infected with type 1
were significantly older than patients infected with non-1 genotypes; however no significant
differences were recorded in gender distribution.
Conclusions: Genotypes other than genotype 1 are quite rare; these are possibly acquired in other
countries. Turkish patients with chronic hepatitis C still represent a rather homogenous group with
genotypic diversity encountered rarely.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Chronic hepatitis C is a global health problem, and according
to recent World Health Organization data the overall pre-* Corresponding author. Tel.: +90 232 3902991;
fax: +90 232 8333318.
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doi:10.1016/j.ijid.2007.07.003valence of hepatitis C virus (HCV) infection is estimated to be
2%, with over 123 million people infected worldwide.1 HCV,
an important cause of chronic hepatitis, cirrhosis, and hepa-
tocellular carcinoma, shows a considerable genetic hetero-
geneity among HCV isolates from all over the world. The
commonly used classification system proposed by Simmonds
et al. is based on heterogeneity and classifies different
genotypes with multiple subtypes on the amount of nucleo-
tide variation. Presently at least six main groups of sequence
variants have been characterized, each group containing aPublished by Elsevier Ltd. All rights reserved.
240 I. Altuglu et al.number of more closely related subtypes (a, b, c, etc.).2,3
The geographical distribution of HCV genotypes may be
useful for epidemiological purposes. Besides its epidemiolo-
gical use, HCV genotype determination is relevant both as a
predictor of response to therapy and to decide on the length
of time required for antiviral treatment.4
Due to the potential clinical implications of different HCV
genotypes, reliable methods are required to classify and
characterize viral genomes from patient specimens. The
reference standard andmost definitive method for determin-
ing genotype involves the direct sequencing of a specific
polymerase chain reaction (PCR)-amplified portion of the
viral genome.5 Restriction fragment length polymorphism
(RFLP), DNA hybridization technologies including line probe
assay (LiPA), PCR amplification with type-specific primers,
and serological typing have been applied to determine HCV
genotypes.6—10
Studies on HCV genotypes in Turkey have determined
genotype 1b to be predominant.11—13 However, studies focus-
ing on the relationship of HCV genotypes in Turkey with
gender, age, and possible risk factors are limited, and there
is a paucity of recent data from large groups. Since genotypes
may influence the clinical outcome of the disease and show
geographic dissimilarities, it is very important to determine
the genotypes in a population; this may also provide informa-
tion for use in clinical management and for the development
of health strategies.
The primary aim of this study was to determine the
recent distribution of various genotypes of HCV in patients
with chronic HCV infection in Western Turkey. Additional
objectives were to determine whether there is any associa-
tion of genotype with gender or age, and to determine
the nucleotide similarities and risk factors of non-1 HCV
genotypes.
Materials and methods
Samples
Serum samples from 345 patients with chronic HCV infection,
sent to the Clinical Microbiology Laboratory of Ege University,
Izmir, Turkey during the period February 2003 to February
2007 for HCV genotyping to assess and plan therapy, were
analyzed in this study. This study was carried out at Ege
University Hospital, a 2000-bed hospital serving as a refer-
ence center (viral confirmation, genotyping) for most of the
western part of Turkey. The study population consisted of 176
males and 169 females, with a mean  SD age of 53.3  12.7
years, range 10—81 years. The serum samples were taken for
extraction of viral RNA and determination of viral genotypes
by reverse transcriptase polymerase chain reaction (RT-PCR)
combined with RFLP analysis.
HCV typing
Extraction of RNAwas carried out using a commercial system
(High Pure Viral Nucleic Acid Kit, Roche Molecular Systems,
Branchburg, NJ, USA) and the RNA pellet was reverse-tran-
scribed to complementary DNA (cDNA) using random hexa-
nucleotide mix and avian myeloblastosis virus reverse
transcriptase. Nested PCR was carried out as described pre-viously by using primers matching conserved regions in the 50
UTR (50 untranslated region). The expected 256-bp length
was confirmed by agarose gel electrophoresis.14
PCR-positive samples were typed by RFLP analysis using
BsuR1-Rsa1, Mva1-Hinf1, and Bsh 12361 (Fermentas Interna-
tional Inc., Canada). After amplification, two aliquots of
product DNA were cleaved with BsuR1-Rsa1 and Mva1-Hinf1
as previously described.15 Subtypes 1a/b were distinguished
by incubating the mixture using the restriction enzyme Bsh
12361. The DNA fragments were electrophoresed on agarose
gel. Different cleavage patterns of the 50 UTR were evaluated
according to the scale of McOmish et al. The nomenclature
for bands produced by BsuR1-Rsa1 and Mva1-Hinf1 follows
that described previously.16
Nucleotide sequencing: To confirm the samples with band
patterns other than genotype 1, the 50 UTR was amplified and
sequenced bidirectionally with internal PCR primers using
the Big Dye Terminator DNA Sequencing Kit (Applied Biosys-
tems, CA, USA) and ABI Prism 310 genetic analyzer (Perkin
Elmer, USA).
Sequences representing all types were obtained from the
European hepatitis C virus database and consisted of sub-
types confirmed by Simmonds.17,18 All the sequences were
aligned by Clustal W method, and phylogenetic comparison
was performed by Lasergene 7.1 (DNAStar Inc., Madison,
USA). Non-1 genotype samples were also analyzed with the
same program.
Patient information
Patient information including gender and age were obtained
from the Clinical Microbiology Laboratory medical records.
Information on possible risk factors for the transmission of
HCV was obtained by short telephone questionnaire.19
Statistical analysis
Statistical analysis was performed with the SPSS 13.0 soft-
ware package (Chicago, IL, USA). Results are expressed as
means  SD or as percentages. The Chi-square test, Stu-
dent’s t-test, and Mann—Whitney U-test were used for data
analysis. The significance level was set at a p-value of
<0.05.
Results
Genotype 1 was observed in 335 of the 345 patients (97.1%)
with chronic HCV infection. Of these, 34 patients showed
infection with subtype 1a (9.9%) and 301 with subtype 1b
(87.2%). Genotype 3 was determined in five patients (1.4% of
all cases), genotype 2 in three patients (0.9% of all cases),
and genotype 4 in two patients (0.6% of all cases). Genotypes
5 and 6 were not found in the study population. The dis-
tribution of HCV genotypes by gender and age of the studied
population is shown in Table 1.
50 UTR (nt102—nt301) sequences from 10 non-genotype 1
samples were compared to 20 GenBank reference sequences,
and analysis indicated that these were closely related to
genotypes 2, 3, and 4 (Figure 1). Sequences from study
specimens were deposited in GenBank (accession numbers
EF540344 to EF540353).
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Figure 1 Genotype determination by phylogenetic tree of the 50 UTR (nt102—nt301) from 10 non-genotype 1 HCV isolates with 20
sequences from GenBank as references. 50 UTR sequences of the isolates are available at GenBank with accession numbers EF540344 to
EF540353.
Table 1 Distribution of HCV genotypes by gender and age in the studied population (N = 345)
HCV genotype
1a 1b 2 3 4
Number (%) 34 (9.9) 301 (87.2) 3 (0.9) 5 (1.4) 2 (0.6)
Gender (%)
Females (n = 169) 14 (8.3) 151 (89.3) 1 (0.6) 2 (1.2) 1 (0.6)
Males (n = 176) 20 (11.4) 150 (85.2) 2 (1.1) 3 (1.7) 1 (0.6)
Age (years)
Mean age (SD) 48.8 (12.8) 54.2 (12.3) 44.3 (21) 38.6 (19) 48 (4.2)
Female (SD) 54.2 (11.9) 53.6 (12.4) ND ND ND
Male (SD) 44.9 (12.2) 54.8 (12.2) ND ND ND
ND, not determined; SD, standard deviation.Nucleotide similarity among isolated genotype 3
sequences ranged from 98.5% to 100% (mean 98.9%), for
genotype 2 sequences this was 100%, and for genotype 4
sequences 99.5% in the aligned segment of 50 UTR (nt102—
nt301). By pair-wise comparison, for genotype 3 sequences,
nucleotide similarity ranged from 94.5% to 99.5% (mean
96.7%), for genotype 2 sequences this ranged from 99.5%
to100% (mean 99.8%), and for genotype 4 sequences this
ranged from 98% to 99.5% (mean 98.9%) in the 50 UTR segment
with the reference sequences (ABO47639 G2a, D50409 2c,
ABO31663 G2k, D177763 3a, D49374 G3b, D63821 G3k,
Y11604 4a, DQ516084 4a, DQ418789 4a, DQ418787 4a).Characteristics of the patients infected with genotypes 2,
3, and 4 along with the possible modes of transmission are
summarized in Table 2.
Discussion
Genotyping of HCV is relevant to the epidemiology of HCV,
vaccine development, clinical management, and assessment
of the risk—benefit ratio of therapeutic measures against
chronic HCV infection.20,21 Geographical differences appear
to exist in the distribution of HCV genotypes. Genotype 1a is
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Table 2 Patients with uncommon hepatitis C genotypes: age, risk factors, and possible modes of transmission
Patient Genotype Age Risk factors, possible modes of transmission Origin of the patient
1 2 21 Thalassemia major, blood transfusions Turkish
2 2 58 Dental surgery Turkish
3 2 60 NA NA
4 3 55 Suspected sexual contact, multiple
number of surgeries
Turkish; lived and worked in Germany
5 3 26 Hemodialysis Turkish
6 3 24 Piercing Turkish
7 3 64 NA NA
8 3 24 NA NA
9 4 51 Blood transfusion Turkish; transfusion was given in Saudi Arabia
10 4 45 Multiple surgeries, use of
non-disposable sharps
Turkish; worked and lived in Iraq,
Russia, and Ireland
HCV, hepatitis C virus; NA, not available.most commonly detected in the USA and Europe. Genotype
1b is distributed worldwide with a high prevalence in the USA
and Europe as well as Japan. Genotype 2 is common in North
America, Europe, and Japan. Genotype 3 is most predomi-
nant in India, Southeast Asia, and Indonesia. Genotype 4
appears to be prevalent in North Africa and the Middle East,
while genotypes 5 and 6 are most frequently reported in
South Africa and the Middle East, respectively.5,22—24
Turkey is located between Europe and the Middle Eastern
countries, which differ from each other in the distribution of
the major genotypes. Studies on HCV genotypes by different
groups in Turkey have found 1b to be the predominant
genotype.11—13 Regional differences in genotype distribution
are not well documented in Turkey. In a study reporting on
HCV genotypes in Southern Turkey, genotype 1b was identi-
fied as the predominant genotype affecting 91% of the
patients.25 Our study results have indicated that in Western
Turkey the genotype distribution is similar.
Studies focusing on the relationship of HCV genotypes with
gender, age, and possible risk factors are limited. In a pre-
vious study performed in 1995, no significant differences in
the distribution of HCV genotypes with respect to age, sex,
and transfusion history were recorded.11 In a recent study
performed on serum samples collected between 1997 and
2000, no association of HCV genotype with patient age was
recorded.13 In an epidemiological report on patients with
end-stage renal disease in Turkey, no significant differences
were determined between 1b and non-1b groups with regard
to age, sex, and HCV RNA levels.26
We aimed to gather recent data on the predominant
genotypes in order to determine if genotype distribution
has changed since the 1990s. Additional objectives were to
determine whether there is any association of genotype with
gender and age, and to determine nucleotide similarities and
risk factors of non-1 HCV genotypes. The earliest study per-
formed in 1995 from the same region found that the predo-
minant genotype was 1b (75.3%), followed by 1a (19.1%), 2
(3.4%), and 4 (2.2%).11 Confirming the aforementioned study,
an earlier report from our department performed on 170
samples collected from 1997 to 1999 revealed similar geno-
type distribution results: 82% genotype 1b, 10% genotype 1a,
2.4% genotype 2, 0.6% genotype 3, and 1.2% genotype 4.12
It is clear that the prevalence of genotype 1b in Turkish
patients has not decreased since these earlier reports, whichis in contrast to results found in Western populations. Sur-
prisingly, genotypes 2, 3, and 4 were found to be rare
compared to prevalences found in other Mediterranean
and European countries. Most developed countries have
accumulated evidence that the predominant source of new
HCV infections within their borders over the past few decades
is injection drug use.13 The majority of infected injection
drug users (IDUs) in Western countries have genotypes 1a and
3a.27—29 It was also recently reported that genotype 4 has
become increasingly prevalent in several European coun-
tries, being prevalent in younger patients and infected
IDUs.30 The reason for the low frequency of non-1 genotypes
observed in Turkish HCV patients may be due to the route of
transmission of infection; the number of IDUs in Turkey is
relatively small.31
Routes of infection were investigated by asking the
patients infected with uncommon HCV genotypes standar-
dized questions (such as whether they had had a blood
transfusion, surgical operation, dental therapy, hemodialy-
sis, tattooing, acupuncture therapy, multiple partners, IV
drug abuse, use of non-disposable sharps, and intrafamilial
transmission).19 History of living/working in another country
was also determined since non-1 genotypes were detected
rarely in the study population. It was noted that three out of
seven patients with uncommon HCV genotypes had a history
of living and working in another country (data on mode of
transmission were not available for the remaining three
patients). Both of the patients with HCV genotype 4 had
been in a Middle Eastern country (Iraq and Saudi Arabia) and
one of them had a history of blood transfusion. Another
patient with HCV genotype 3 infection had lived and worked
in Germany for years. Due to the small number of patients
infected with non-1 HCV genotypes caution must be used in
interpreting these data.
Previous studies from different countries have analyzed
genotype distribution in relation to patient age. In some
studies, it was determined that patients infected with geno-
types 1b or 2wereolder thanpatients infectedwith genotypes
1a, 3, or 4.29,32 Analysis of the genotypedistribution according
to age showed that patients infected with type 1 (mean  SD
age, 53.6  12.4 years) were significantly older than patients
infected with non-1 genotypes (mean  SD age, 42.2  16.8
years; p = 0.03). When genotype distribution (genotype 1 and
non-1 (genotypes 2, 3, and 4)) was investigated in relation to
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0.333, p > 0.05).
Although p values were calculated, the relatively small
number of patients with non-1 genotypes is the limitation of
this study. The mean age  SD of females infected with
subtype 1a was statistically higher than that of males
(54.2  11.9 years vs. 44.9  12.2 years; p = 0.039). How-
ever, we found no significant difference in the mean
age  SD of females and males in the 1b-infected group
(53.6  12.4 years vs. 54.8  12.2 years; p = 0.4). For
patients infected with genotypes 2, 3, and 4, statistical
analysis was not performed due to the small number of
patients in each group.
In the studied population, confirming earlier studies, the
majority of patients with HCV infection had genotype 1b,
followed by 1a. The prevalence of genotype 1b in Turkish
patients has not decreased since these earlier reports.
Genotypes other than genotype 1 are quite rare, and it is
possible that in some cases these were acquired in other
countries. The results of our study indicate that Turkish
patients with chronic hepatitis C still represent a rather
homogenous group with genotypic diversity encountered
only rarely.
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